Quince Therapeutics (NASDAQ:QNCX) Research Coverage Started at Citizens Jmp

Citizens Jmp initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage issued a strong-buy rating and a $9.00 target price on the stock.

QNCX has been the subject of several other reports. Wall Street Zen cut Quince Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. D. Boral Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of Quince Therapeutics in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Quince Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $8.29.

Quince Therapeutics Price Performance

Shares of QNCX stock opened at $1.67 on Tuesday. The stock’s fifty day simple moving average is $1.54 and its 200 day simple moving average is $1.36. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The firm has a market cap of $89.55 million, a price-to-earnings ratio of -1.20 and a beta of 1.02. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.05 and a quick ratio of 4.05.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, analysts expect that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

Hedge funds have recently modified their holdings of the stock. Two Sigma Investments LP bought a new stake in Quince Therapeutics during the fourth quarter worth $57,000. Northern Trust Corp increased its stake in shares of Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after purchasing an additional 16,501 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Quince Therapeutics by 10.9% in the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock valued at $703,000 after purchasing an additional 36,807 shares during the period. Shay Capital LLC lifted its stake in Quince Therapeutics by 60.8% in the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock valued at $518,000 after purchasing an additional 104,616 shares during the last quarter. Finally, Intellectus Partners LLC bought a new position in Quince Therapeutics during the first quarter worth about $71,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.